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Liver Transplantation for Fulminant Hepatic Failure 
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Leonard Makowka, Robert D. Gordon, and Thomas E. Starzl 
FULMINANT hepatic failure (FHF) is the clinical syn-drome associated with acute massive necrosis of the 
liver that has been functioning normally before the onset of 
illness. It is characterized by increasing jaundice, decrease in 
the size of the liver, fetor hepaticus, coagulopathy, renal 
failure, hepatic encephalopathy, and eventual death. The 
mortality rate for FHF when associated with grade IV coma 
is 80 to 95%.1.2 The symptoms of hepatic failure (especially 
encephalopathy) develop within eight weeks from the onset 
of illness. 
Various modalities of medical treatment have been 
applied for FHF, but none of these has had a significant 
impact on the lethal prognosis.3•5 With the significant 
improvement in the results of liver transplantation over the 
past several years,6.7 liver replacement has become a practi-
cal therapeutic option for advanced FHF.8•9 We report here 
our experience with liver transplantation for FHF in 42 
patients under the cyc1osporine (CsA)/steroid immunosup-
pressive therapy. 
CASE MATERIAL AND METHODS 
Between January 1980 and December 1987, 1061 patients under-
went orthotopic liver transplantation under CsA/steroid therapy. Of 
these, 42 patients (4%) had FHF of various causes. There were 21 
males and 21 females. The ages of the patients ranged from eight 
months to 62 years, with a mean of 22.9 years (SD 15.9 years). FHF 
was suspected from the rapidly progressive clinical course (maxi-
mum of eight weeks from the onset of the illness to obvious liver 
failure) and was confirmed by histologic examination of the excised 
liver. The patients with histologic evidence of chronic liver disease 
(significant fibrosis and early cirrhosis) and/or a clinical course of 
longer than eight weeks were excluded from this study. Also 
excluded were the patients with the fulminant form of Wilson's 
disease (subacute Wilson's disease), acute exacerbation of previ-
ously unrecognized chronic liver disease, and retransplants. 
The patients with FHF were closely observed and managed 
preoperatively in the intensive-care unit. The clinical course, signs 
and symptoms of hepatic failure, blood chemistry, coagulation 
parameters, the size of the liver, neurologic tests (CT, EEG, 
intracranial pressure), and liver biopsy findings (where feasible) 
were followed closely. The decision to proceed with OLTx was made 
by a group of experienced physicians and surgeons, all of whom 
agreed upon the inevitable death of the patient without liver 
replacement. 
At the time of transplantation 15 patients (36%) were in grade I or 
II coma, 13 (31%) in grade III coma, and 14 (33%) in grade IV 
coma. All patients had uncorrectable profound coagulopathy, even 
after replacement therapy (prothrombin time> 20 seconds). Ten 
patients had clinical bleeding (from the GI tract and/or from needle 
puncture sites), 14 had renal failure, 18 required respiratory support, 
seven had hypoglycemia, four had sepsis (positive blood culture), 
three had hemodynamic instability requiring large amounts of 
vasopressor support, and five had uncorrectable metabolic acidosis. 
The survival rates as of August I, 1988, were calculated by the life 
table method of Kaplan-Meyer. The statistical comparisons were 
made by the chi-square test and the Cox-Mantel method. The p 
value of <0.05 was considered statistically significant. 
RESULTS 
Causes of FHF and Histopathology 
The causes of FHF were hepatitis B in eight patients, toxic 
hepatitis in nine patients, so-called non-A, non-B viral hepa-
titis (HNANB), or hepatitis of undetermined etiology in 24 
patients, and hepatic artery thrombosis after excision of a 
pheochromocytoma in one patient. Of the nine patients with 
toxic hepatitis, anesthetic agents such as halothane were 
suspected in three, valproic acid (Oepakene) in one, gold 
sodium thiomalate in one, phenytoin sodium (Oilantin) in 
one, methyl-ethyl-ketone (paint solvent) in one, and probably 
acetaminophen in two. 
The weight of the excised liver in the adult-size patients 
(>45 kg) ranged from 420 g to 3200 g, with a mean of 1002 g 
(SO 586 g). Twenty-seven patients had massive necrosis, and 
15 had submassive necrosis of the hepatocytes. None of these 
patients had either significant fibrosis or cirrhosis. 
Survival 
The overall actuarial survival rates as of August 1, 1988, are 
shown in Figure 1: 73.8% at one month, 64.3% at three 
months, 61.9% at six months, 59.4% at one year, and 45.8% 
at two, three, and four years. 
Seven of the eight (87.5%) patients with hepatitis Bare 
alive (Fig 2). The only death in this group occurred intra-
operatively, as a result of pulmonary emboli during the use of 
veno-venous bypass. The survival rates of the nine patients 
with toxic hepatitis were 66.7% at one month, 44.5% at three 
and six months, 33.3% at one year, and 16.7% at two years; 
only two of the nine patients (22%) are still alive (Fig 2). The 
survival rates for the 24 patients with so called non-A, non-B 
hepatitis were 75% at one month, 66.7% at three months, 
62.5% at six months and one year, and 43.8% at two, three, 
and four years (Fig 2). Finally, one patient with hepatic 
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Fig 1. FHF versus general OL Tx population: survival. 
artery thrombosis after resection of an extensive retroperito-
neal pheochromocytoma died soon after transplantation. 
Risk Factors 
Several risk factors were identified; their influence upon one-
and three-month survival is analyzed and summarized in 
Table 1. 
Stage IV coma, clinical bleeding, and renal failure were 
identified as significant risk factors (p < 0.05). The need for 
pretransplant respiratory support and hypoglycemia were 
probable risk factors (0.05 < P < 0.1). Sepsis, uncorrectable 
metabolic acidosis, and hemodynamic instability requiring 
high doses of vasopressors appeared to be significant risk 
factors, but the numbers were too small for meaningful 
analysis. 
Neurologic Recovery 
The neurologic recovery was studied in 36 patients who lived 
for more than one week with satisfactory graft function. 
Thirteen of the 14 (92.9%) patients with grades I or II 
coma had complete neurologic recovery. One had partial 
recovery, but died from an in:racranial hemorrhage 20 days 
after the first and 12 days after the second transplant. All of 
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Fig 2. FHF: Survival by diagnosis. 
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the 12 (100%) patients with grade III coma had a complete 
neurologic recovery. However, the neurologic recovery was 
complete in only five of the 10 (50%) patients with grade IV 
coma. Severe cerebral dysfunction persisted in two (20%) 
patients, and the coma progressed to brain death in three 
(30%) of the 10 patients (p < 0.05). 
Recurrence of the Primary Disease 
Of the eight patients with hepatitis B, all were positive for 
HBsAg, four were positive for HBeAg, and two had the 
antidelta antibody at the time of transplantation. All of the 
seven patients who survived the operation received a large 
dose (50 to 100 ml) of anti-hepatitis B immunoglobulin 
during the anhepatic phase of OL Tx, then one day, one 
month, and two months after transplantation. All seven 
patients became HBsAg negative and HBsAb positive for 
one to three months. Later, however, five of the seven 
patients became HBsAg .,ositive again. Two of the seven 
remain HBsAg negative 18 months and 4.5 years after 
transplantation, respectively, and both have developed 
HBcAb. Two of the four patients who were HBeAg positive 
became negative after transplantation; however, two other 
patients who were negative for HBeAg preoperatively 
acquired the antigen after transplantation. 
Two patients who lost the HBsAg after transplantation 
have not developed any clinical or histologic evidence of 
recurrent hepatitis B. Three of the five patients who are still 
positive for HBsAg after transplantation developed clinical 
and histologic recurrence of the disease. One of these 
required retransplantation after 21 months for hepatitis B, 
and two are waiting for retransplantation because of chronic 
rejection and hepatitis B. 
Of the 15 patients with so-called non-A, non-B viral 
hepatitis who survived more than six months, two became 
positive for HBsAg after transplantation. One patient 
required retransplantation for chronic active hepatitis B at 
18 months, and the other still had normal liver function four 
years later. Although difficult to document, three other 
patients have developed recurrence of their non-A, non-B 
hepatitis by histologic examination of the liver. Two of the 
three patients have good to fair liver function after 2.5 and 
four years. The other patient is deeply jaundiced and waiting 
for retransplantation 27 months after his first liver trans-
plantation. 
Causes of Death 
A total of 21 patients died during the observation period. Six 
patients died primarily from infectious complications. Five 
deaths were primarily neurologic, including three from brain 
death. Despite the high incidence of primary non function of 
the initial grafts (9 of 42, or 21.4%), only three patients died 
as a result, and the remaining six patients were rescued by 
timely retransplantation. Three patients died of hepatic 
failure due to acute and chronic rejection with or without 
regrafting. Three patients died of technical failure, and one 
patient died of a posttransplant lymphoproliferative disor-
der. 
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Table 1. Number of Deaths at One and Three Months Without or With the Risk Factor 
Risk Factor No of Deaths No Yes p 
Coma stage 1 mo 4/28 (14.3%)* 7/14 (50%)t <0.05 
3mo 8/28 (28.5%)* 10/14 (71.4%)t <0.05 
Clinical bleeding 1 mo 2/32 (6.30f0) 6/10 (60%) <0.001 
3mo 4/32 (130f0) 7/10 (70%) <0.01 
Renal failure 1 mo 2/32 (9.4%) 5/10 (50%) <0.05 
3mo 6/32 (18.8%) 61 10 (600f0) <0.05 
Respiratory support 1 mo 1/24 (4.20f0) 7/18 (38.9%) <0.05 
3mo 4/24 (16.70f0) 8/18 (44.4%) <0.1 
Metabolic acidosis 
Hypoglycemia 
Hemodynamic instability 
Sepsis 
1 mo 6/37 (16.2%) 5/5(100%) <0.001 
1 mo 7/35 (200f0) 4/7 (57.1%) <0.1 
-Grades I to III coma. 
tGrade IV coma. 
tToo few cases for analysis. 
Current Status of Surviving Patients 
1 mo 
1 mo 
3mo 
Fourteen ofthe 21 survivors (66.7%) have good liver function 
(SGOT < 100 U and/or total bilirubin < 2 mg%) between 
seven months and four-plus years after transplantation. Four 
(19%) have fair liver function (SGOT 100 to 200 U and/or 
total bilirubin 2 to 4 mg%) between one and four years, and 
three (14.3%) have poor liver function between one and two 
years after transplantation. These three patients are waiting 
for retransplantation. 
Aplastic Anemia 
Four of the 24 (16%) patients with non-A, non-B viral 
hepatitis developed aplastic anemia, a known serious compli-
cation of non-A, non-B viral hepatitis. IO•1l Three of the four 
patients recovered from aplastic anemia, but one still 
remains severely pancytopenic ten months after transplanta-
tion. 
DISCUSSION 
Survival rates after liver transplantation for fulminant hepa-
tic failure were significantly worse than for the 1061 patients 
who received liver grafts during the same period (Fig 1). The 
difference was most significant during the first three months. 
The lower survival rates of patients with FHF were related to 
the grave condition of most of the recipients prior to liver 
replacement. Grade IV encephalopathy, renal failure, 
obvious bleeding diathesis, metabolic acidosis, hypoglycem-
ia, hemodynamic instability, sepsis and respiratory failure 
are, singularly or in combination, ominous prognostic signs of 
FHF (Table 1). The survival rates of those who did not have 
these risk factors were as good as the overall survival rates of 
the other 1061 transplant recipients. 
To improve the survival rate after liver transplantation for 
FHF, the potential recipients should be transferred to liver 
transplant centers where the candidates can be closely moni-
tored and aggressively treated by experienced staff. Should a 
liver replacement be deemed unavoidable, it must be carried 
out immediately before ominous complications develop. The 
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potentially dangerous procedure of liver biopsy will be 
important in the assessment of some candidates. With accu-
mulation of experience in the treatment of FHF, more 
accurate and earlier prognostic indicators of acute massive 
hepatic necrosis can hopefully be established. 
It is encouraging to note that none of the viral hepatitis 
recurred in a fulminant form after successful liver transplan-
tation, including hepatitis B. Although the number of cases 
was small, the survival rates of patients with fulminant 
hepatitis B after transplantation were better than the overall 
survival rates (Figs 1 and 2). Two of the seven one-year 
survivors have lost the HBsAg and acquired HBcAb and 
have remained antigen negative for 18 months and nearly 
five years. The liver function tests of these two patients are 
completely normal. The remaining five patients became 
positive for HBsAg again a few months after liver replace-
ment, and all five have developed clinical and histologic 
recurrence of hepatitis B. Two of the five will require 
retransplantation because of chronic rejection and recurrent 
hepatitis B. One patient was retransplanted for recurrent 
hepatitis B, and although the HBsAg remains positive, the 
patient has normal liver function five months after retrans-
plantation. The remaining two patients have elevated levels 
of transaminases with normal serum bilirubin. 
The recurrence of non-A, non-B viral hepatitis was 
observed in only three of the 15 six-month survivors, 
although its documentation is quite difficult. Nevertheless, 
11 of the 12 surviving patients have normal liver function 
tests eight to 54 months after transplantation. 
These data indicate that viral hepatitis, including hepatitis 
B, does not seem to be a contraindication for liver transplan-
tation. 
SUMMARY 
The actuarial survival rates of patients with fulminant 
hepatic failure were 73.8% at one month, 64.3% at three 
months, 61.9% at six months, 59.4% at one year, and 45.8% 
at two, three, and four years after liver transplantation. 
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These survival rates were significantly lower thcftl the overall 
survival rates of 1061 patients transplanted during the same 
period, mainly because of the grave condition of these 
patients. Fulminant viral hepatitis, including hepatitis B, is 
not a contraindication for liver transplantation. Liver trans-
plantation has established its significant role in the treatment 
of fulminant hepatic failure of various causes. 
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